[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594623":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":58,"collaborators":26,"id":63,"slug":26,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Danish Headache Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calcitonin gene-related peptide (CGRP)","EXPERIMENTAL","CGRP will be administered by intravenous infusion.",[13],"Drug: Calcitonin-gene related peptide (CGRP)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (isotonic saline) will be administered by intravenous infusion.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Calcitonin-gene related peptide (CGRP)","The participants will receive a continuous intravenous infusion of 1.5 μg\u002Fmin of CGRP over 60 minutes.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"The participants will receive a continuous intravenous infusion of 60 mL of placebo (isotonic saline) over 60 minutes.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Haidar Al-Khazali, MD","CONTACT","+4541598494","haidardk@hotmail.com",{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},"Hakan Ashina, MD, PhD","+4528102495","haakan.ashina@regionh.dk",[41],{"facility":42,"status":43,"city":44,"state":26,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Rigshospitalet Glostrup","RECRUITING","Glostrup Municipality","2600","Denmark",{"type":48,"coordinates":49},"Point",[50,51],12.40377,55.6666,{"lat":51,"lon":50},[54,55,56],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},{"name":32,"role":57,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":62,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Haidar Al-Khazali","Principal Investigator","Rigshospitalet, Denmark","100594623",false,"NCT07021859","Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide","Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria\n* ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures.\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache\n* History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Aura within 48 hours of infusion start","ALL","18 Years","65 Years",{"count":73,"type":74},21,"ESTIMATED","INTERVENTIONAL",[77],"NA","Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.",[80,81],"Migraine Aura","Migraine With Aura",[83,84,85],"Migraine","Aura","Calcitonin gene-related peptide","2025-08-03",{"date":88,"type":89},"2025-08-06","ACTUAL",{"date":91,"type":89},"2025-06-27",{"date":93,"type":74},"2026-12-30",{"name":5,"class":6},1]